Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/05/26
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026GlobeNewsWire • 06/03/26
Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASHGlobeNewsWire • 05/27/26
Madrigal to Present New Data from the Company's MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension RiskGlobeNewsWire • 05/20/26
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock UpZacks Investment Research • 05/07/26
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 05/06/26
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH PipelineGlobeNewsWire • 05/05/26
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal PharmaceuticalsBusiness Wire • 05/05/26
Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/29/26
Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026GlobeNewsWire • 04/22/26
Madrigal (MDGL) Surges 12.3%: Is This an Indication of Further Gains?Zacks Investment Research • 03/27/26
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From NowThe Motley Fool • 03/25/26
Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care ConferenceGlobeNewsWire • 02/24/26
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock DownZacks Investment Research • 02/20/26
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial ResultsGlobeNewsWire • 02/19/26